Method for heterotopic ossification surgical treatment with local neural simulation of spastic syndrome

FIELD: medicine.

SUBSTANCE: for surgical treatment of heterotopic ossification with local neural simulation of the patient spastic syndrome, preliminary multilayer spiral computerized tomography (CT) is used to ptovide spatial imaging of bone structures and ossificates. The method of magnetic resonance imaging reveals the ossificate soft tissue component which is not visualized by MSCT. Then the heterotopic ossificate maturity stage is determine by calcium-phosphorus metabolism indices - alkaline phosphatase, osteocalcin, and bone matrix formation marker PINP - N-terminal pro-peptide of type 1 procollagen in patient's venous blood. If the measured parameters of N-terminal propeptide of type 1 procollagen - PINP are less than 76 ng/ml, even in case of an isolated lesion of one elbow or knee joint, alkaline phosphatase level is in the range 40-150 U/l and osteocalcin level is within 11-46 ng/mL, completion of osteoid formation and mineralization with formation and maturation of newly formed cancellous bone is concluded. In this case, surgical ossificates removal from the affected joint is prescribed. At that, local neural simulation of spastic syndrom is performed prior to surgical removal of ossificates, until it a stable decrease to the level of 0 to 1 on Ashworth scale is reached. Next, surgical treatment is performed involving ossificate resection or removal of an adequate volume of heterogeneous bone to restore the functionally adequate range of motion in the affected joint.

EFFECT: possibility of surgical treatment of heterotopic ossification in patients with spastic syndrome, minimizing the risk of complications during surgical treatment, and pathological process recurrence.

3 cl, 5 ex

 



 

Same patents:

FIELD: medicine.

SUBSTANCE: saliva of affected child is analysed by method of infrared spectroscopy, value of ratio of peak height with maximum at 1070 cm-1 to peak height with maximum 1025 cm-1 is calculated. If value of ratio is in range from 1.1 to 1.9 nonspecific ulcerative colitis is diagnosed, and if value of said ratio is from 2.0 to 4.6 Crohn's disease is diagnosed.

EFFECT: invention ensures less invasive and simpler differential diagnostic of NUC and Crohn's disease in children, ensures simplification and acceleration of diagnosis determination.

4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method of diagnosing bipolar affective disorder. The essence of the method consists in the fact that reliable differences in the spectrum of protein distribution in blood serum without proteins albumin, immunoglobulin G, immunoglobulin A, antitrypsin, transferin and haploglobin in patients with endogenic psychosis. If protein spots are detected on electrophoretic gel in areas with the molecular weight of 200, 84, 75, 49, 40 kDa in the patient with endogenic psychosis, bipolar affective disorder is diagnosed.

EFFECT: application of the claimed method makes it possible to increase accuracy in diagnostics being simple in realisation.

2 ex

FIELD: medicine.

SUBSTANCE: method involves determining female serum cytotoxicity to male lymphocytes, including a combined culture with reference male and analysed female serum in a 96-well tray in the presence of the nutrient medium RPMI 1640 in a CO2 incubator. One day later, lymphocytes are counted in the well in a Goryaev's chamber with the male (reference) and female (analysed) serum. That is followed by determining a cytotoxic index (CI), which represents a quotient of the analysed cell count and the reference cell count. The normal cytotoxic index makes approximately 0.7 and less.

EFFECT: invention enables studying the responses of female humoral immune factors to male antigens and evaluating a risk of miscarriage, early spontaneous abortions and missed miscarriages.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a high-sensitivity method for measuring the amount of individual's blood plasma glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts. The high-sensitivity method for measuring the amount of glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts is characterised by the fact that a mixture of individual's blood plasma with methanol or ammonia water in the specific concentration is introduced into a solid phase having the reverse-phase distribution function and the anion exchange function; the solid phase is then washed with a cleaning fluid that is a single-component fluid or a mixed fluid of at least two components specified in a group containing water, alkali, alcohol and acetonitrile. That is followed by elution from the solid phase in acid alcohol specified in formic acid - methanol or formic acid - ethanol; that is followed by the stage of measuring glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts by liquid chromatography - mass spectrometry or liquid chromatography - mass spectrometry/mass spectrometry.

EFFECT: high-sensitivity method enables detecting and measuring the amounts of individual's blood plasma glycyrrhizin, glycyrrhetinic acid and their pharmaceutically acceptable salts.

4 dwg, 17 tbl, 7 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises selection of only living, mature females of Trichuris vulpis from colon, blind gut of wild and/or domestic carnivorous animals infected spontaneously with whipworms in the study with helminthological methods when autopsy, into separate tubes with officinal isotonic solution (0.9%) of sodium chloride (solutio Natrii chlorati isotonica) and the exposure of the tubes with the females of Trichuris vulpis at t = 37.5-39°C for 5 hours under conditions of a thermostat.

EFFECT: method enables to select a large amount of fertilised eggs of T vulpis, not contaminated with particles of undigested feed, the particles of destroyed tissue of genitals of female of T vulpis and secondary bacterial microflora.

2 ex

FIELD: medicine.

SUBSTANCE: patient's peripheral venous blood is recovered to analyse genetic polymorphisms of coagulation factors VII 10976G/A FVII. A birth weight of a newborn of a woman delivering not for the first time in the stage of 37 and more weeks of pregnancy is determined by equation: y=6123.431-25.579x1+0.267x2+205.739x3, wherein y is an anticipated newborn's weight, x1 is a female's height in centimetres; x2 is an infant's weight at the previous delivery in grams, x3 is a genetic version of 10976G/A FVII locus with x3=1 for 10976 GG FVII genetic type, x3=2 for 10976 GA and 10976 AA FVII genetic types. A birth weight of a newborn of a woman delivering for the first time in the stage of 37 and more weeks of pregnancy is determined by equation: y=6278.037-21.739x1+232.170x2, wherein x1 is a female's height in centimetres; x2 is a genetic version of 10976G/A FVII locus with x2=1 for 10976 GG FVII locus, x2=2 for 10976 GA and 10976 AA FVII genetic types.

EFFECT: invention enables improving the prevention and treatment of the pregnancy complications.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: pre-operative fasting venous blood 1 ml is sampled at room temperature 20-24°C into an anticoagulant-free vacuum system (test tube). The test tubes are delivered in a sealed container at temperature 2-8°C for 2 hours to a laboratory for immunoenzyme assay and analysed to determine anti-thyroid stimulating hormone receptor antibodies. If the antibody level is 1.5 units/l or more, a thyroidectomy is performed, whereas the antibody level of less than 1.5 units/l requires performing a subtotal thyroid resection according to standard techniques.

EFFECT: invention enables reducing a probability of recurrent thyrotoxicosis in the patients after subtotal thyroid resection.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to a method for the prediction of a risk of early microvascular complications in the children suffering from type 1 diabetes mellitus. The substance of the method consists in defining a duration of the diseases in years, the patient's age in years, a desquamated endothelial cell count, high-density lipoprotein cholesterol, total cholesterol, triglycerides, atherogenic index, glycohaemoglobin, average daily glycaemic level; making a linear regression analysis and calculating a risk ratio (R) of early microvascular complications in the children suffering from type 1 diabetes mellitus by formula. If the risk ratio is ≥1, the high risk of early microvascular complications during one year is predicted; the ratio < 1 shows the low risk of microvascular complications during one year.

EFFECT: using the declared method enables increasing the prediction accuracy of microvascular complications in the children with type 1 diabetes mellitus.

2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and can be used for patient's status monitoring. A method for setting a time-varying physiological parameter warning signal involves patient's controlled parameter monitoring, comparing the controlled parameter to an initial cut-off criterion, varying the cut-off criterion temporarily by a cut-off criterion of deterioration after the therapy, and then after a certain period of time, by the cut-off criterion after the administration. The time allowed involves comparing the controlled parameter to the cut-off criterion of deterioration, and after the time allowed - to the cut-off criterion after the administration. The warning signal is initiated in response to the controlled parameter of one or more initial cut-off criteria, the cut-off criterion of deterioration and the cut-off criterion after the administration. The group of inventions also refers to a machine-readable carrier with software for implementing the method and to a system for user warning on the controlled parameter variation.

EFFECT: group of inventions provides higher accuracy and rate of assessing the patient's status according to the conducted therapy.

15 cl, 6 dwg

FIELD: medicine.

SUBSTANCE: invention can be used for the purpose of the early prediction of cystic periventricular leukomalacia (PVL) in the newborns with very low (VLBW) or extremely low body weight (ELBW). Substance of the method: the newborns with VLBW and ELBW on the 3rd-7th day of life are examined to assess the perinatal medical history, namely the presence of chorioamnionitis and amniotic fluid nature, 5th minute Apgar score, the absence of prolonged artificial pulmonary ventilation, a severity of respiratory distress syndrome, the presence of pneumonia, sepsis, convulsive disorder, anaemia, laboratory signs of the systemic inflammatory reaction, average values of carbon dioxide, anionic bicarbonate and base deficiency in capillary blood, interleukine-6 and receptor interleukine-1 antagonist in venous blood serum. Each sign is assigned with a prognostic coefficient (PC). That is followed by determining total PC, and it is expected cystic PVL that is decided for if total PC is at least (+)9.5, whereas no cystic PVL is expected if total PC is (-)9.5 or less.

EFFECT: invention provides the early (for the first 7 days of life) prediction of cystic periventricular leukomalacia in the most susceptible category of patients that are children with very low and extremely low birth weight.

6 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the pharmaceutical industry, namely represents a method for ensuring a uniform dissolution profile of a pharmaceutical composition of cyclobenzaprine containing inert coated particles with the cyclobenzaprine containing composition of a drug layering for forming IR granules to be coated with a prolonged-release coating for forming ER granules.

EFFECT: developing the method for ensuring the uniform dissolution profile of the pharmaceutical composition.

53 cl, 6 ex, 5 dwg, 4 tbl

FIELD: medicine.

SUBSTANCE: analgesic preparation causing medication overuse headache are withdrawn; a detoxification therapy is conducted; an analgesic alternative is provided; a preventive medication and a behaviour therapy are applied. The preventive medication represents single intramuscular administration of xeomin into temporal muscles in a dose of 25 units in each frontal and occipital muscle in a dose of 12.5 units. The preventive medication follows the detoxification therapy.

EFFECT: considerable reduction of the recurrence number by relieving the reflex pericranial muscle and expression line tension.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents a combined analgesic and anti-spasmodic drug containing caffeine and drotaverine hydrochloride, characterised by the fact that as active substances it additionally contains ketorolac or a compound thereof, such as ketorolac tromethamine and diphenylhydramine in the amount of: ketorolac or a compound thereof, such as ketorolac tromethamine 5 - 40 mg, caffeine 50 - 100 mg, diphenylhydramine 20 - 50 mg, drotaverine hydrochloride 40 - 80 mg.

EFFECT: invention provides developing the drug possessing strong analgesic action in moderate or severe pain syndromes, various cramping pains.

2 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, namely to pharmaceutical industry. Complex of carbamazepine-cyclodextrin inclusion is obtained by mixing modified cyclodextrin and carbamazepine in physiologically acceptable liquid. Modified cyclodextrins include 2-hydroxylpropyl-bata-cyclodextrin and sulfonylcyclodextrins. Physiologicallyt acceptable liquid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological salt solution and analogous liquids, suitable for parenteral introduction.

EFFECT: obtaining complex of carbamazepine-cyclodextrin inclusion which can be applied for parenteral introduction of carbamazepine.

24 cl, 9 tbl, 9 ex, 7 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to novel prodrugs of biologically active 2,4-pyrimidine diamine compounds with structural formula given below, hydrate, solvate and pharmaceutically acceptable salts thereof. The compounds have properties for inhibiting cascade transmission of a signal from an Fc-receptor, such as FcαRI, FcγRI, FcγRIII and FcεRI, degranulation or Syk kinase activity. Structural formula:

EFFECT: compounds can be used to treat or prevent rheumatoid arthritis and autoimmune diseases.

25 cl, 21 cl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery and intensive therapy, and can be used for treatment of intraabdominal hypertension syndrome. For this purpose decompressive laparotomy and probe decompression of intestine are carried out. In post-operational period peridural anesthesia is performed. Additionally in said period myorelaxant is introduced intravenously in dose sufficient for elimination of tone of anterior abdominal wall muscles, at the background of artificial lung ventilation.

EFFECT: method allows to eliminate impact of increase of tone of anterior abdominal wall muscles onto intraabdominal pressure due to introduction of myorelaxant in required dose.

2 ex

FIELD: medicine.

SUBSTANCE: group of inventions concerns biology and medicine. There is disclosed method of biotreatment blood serum production involving electrostimulation of an animal, other than a human, blood drawing of specified animal, serum separation from specified blood and gamma irradiation in a dose 10 to 40 kGy. There is offered blood serum product and pharmaceutical composition containing said blood serum product, and also their application for treatment of various diseases.

EFFECT: invention provides production of biotreatment animal's blood serum applied for treatment of wide range of diseases, including epileptic attacks and apoplexy.

24 cl, 4 ex, 7 tbl, 11 dwg

FIELD: chemistry.

SUBSTANCE: in derivatives of colchicine of general formula (I) X is oxygen or sulphur, particularly - to 3-O-β-D- xylopyronozyl-3-O-demethyltiocolchicine and 3-O-β-L- xylopyrano-zyl-3-O-demethyltiocolchicine.

EFFECT: efficient for preparation of miorelaxant medications, medications for treatment of inflammatory conditions, which influence muscular system, and antigout medications.

11 cl, 2 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention suggests pharmaceutical compositions intended for sublingual intake, as active ingredient of which agonist of central receptor of benzodiazepines is used, selected from the following list: diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam, midazolam-maleate, in mixture with pharmaceutical excipient, which constitutes at least 70% of total weight of ready composition, and which contains lactose in amount from 40 to 45 wt %, corbite in amount from 15 to 27 wt % and cellulose in amount from 12 to 16 wt %. Excipient components lactose: cellulose: corbite are in ratio, approximately, 3:1,4-2,7:1.

EFFECT: ensuring fast action of benzodiazepines, similar to action of analogous preparations for injections and higher action than after peroral intake.

7 cl, 4 tbl, 8 ex

FIELD: medicine, pharmacy, pharmacology.

SUBSTANCE: invention relates to a pharmaceutical composition comprising the medicinal preparation afobasol as an active component. Indicated pharmaceutical composition is prepared as a tablet formulation and comprises medicinal preparation afobasol, i. e. 5-ethoxy-2-[2-(morpholino)ethylthio]benzimidazole hydrochloride, eliciting the expressed anxiolytic activity in the broad range of doses. The composition comprises small amounts of special additives, such as lactose, starch, polyvinylpyrrolidone, stearic acid or stearate. Invention provides easy release of active component that provides its high bioavailability. Tablets satisfy all requirements of the State Pharmacopoeia of XI edition.

EFFECT: improved and valuable pharmaceutical and medicinal properties of pharmaceutical composition.

8 cl, 1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: device for correction of sleep characteristics contains sensor for registration of electrodermal activity EDA, connected with unit of analysis and extraction of signals of skin-galvanic responses SGR, generator of stimulating electric pulses, on-skin electrodes and control unit. Device is made in form of monoblock with possibility of fastening on user's palm. Monoblocks case has front and back side, and fastening elements. Three electrodes, placed with possibility of galvanic connection with skin of user's hand palm, are located on back part. Measuring electrode is connected to input of sensor for EDA registration, with stimulating electrode being connected to output of generator of electric pulses, with the third one being common neutral electrode of galvanic circuits of said sensor and generator. Units of analysis and extraction of SGR signals and control unit are made on base of microprocessor with possibility of periodical control of current condition of galvanic contact of electrodes with skin, cyclic measuring of SGR intensity and supply of stimulating electric pulses in pauses between SGR measuring, and provide three modes of functionality: sleeping mode - in absence of galvanic contact of electrodes with skin; mode of EDA registration - in presence of galvanic contact of electrodes with skin, including extraction of SGR pulses and counting their quantity N for given time interval and comparison with threshold value; mode of stimulation - if quantity N of SGR pulses exceeds threshold value, including periodical supply of electric pulses to stimulating electrodes during specified time interval.

EFFECT: invention application makes it possible to extend arsenal of technical means for correction of patient's physical condition during sleep and further wakefulness, increase index of slow-wave sleep stage, power of delta-waves and therefore deepen sleep sensation, phases of fast eye motions, and increase sleep quality in general.

9 cl, 10 dwg

Up!